3545 CRAY COURT, SAN DIEGO, CA
Contingent Value Rights Agreement
Other Events
Shareholder votes
Mirati Therapeutics' KRAZATI Gets CHMP Positive Opinion for Advanced NSCLC
Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Strengthens and Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics
Announces Departure of Chief Financial Officer Laurie Stelzer
Q3
Q2
Q1
FY 2022
FY 2021
Notice of Suspension of Duty to File Reports
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Merger Proxy Statement
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
S-8 POS